Carl Zeiss Meditec : Q3 review – more visibility after severe cut, Microsurgery very weak
>In line with expectations lowered at the preliminary results - In June 2024, Carl Zeiss Meditec already released preliminary 8 months results. Q3 2024 revenues reached € 539.4m (+0.8% y-o-y) 5%/0% vs ODDO BHF/consensus. Adj. EBIT of € 64.1m (-38.1% y-o-y, margin 11.9%) was in line consensus. EBIT reached € 54.4m (-46.1% y-o-y, margin 10.1%) and was -2% vs consensus. EPS of € 0.38 compares to expectations of € 0.28 and € 0.46 for the consensus. Ophthalm...Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.